You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorprothixene
Accession NumberDB01239  (APRD00718)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Structure
Thumb
Synonyms
Alpha-Chlorprothixene
Chlorprothixen
Chlorprothixine
Chlorprotixen
Chlorprotixene
Chlorprotixine
Chlothixen
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ClothixenYoshitomi
CloxanOrion
TaractanRoche
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9S7OD60EWP
CAS number113-59-7
WeightAverage: 315.86
Monoisotopic: 315.084847978
Chemical FormulaC18H18ClNS
InChI KeyInChIKey=WSPOMRSOLSGNFJ-VGOFMYFVSA-N
InChI
InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7+
IUPAC Name
[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]dimethylamine
SMILES
[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Diarylthioether
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.
PharmacodynamicsChlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine analgesic effects. An antiemetic effect, as with most antipsychotics, exists. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side-effects. Chlorprothixene is structurally related to chlorpromazine, with which it shares in principal all side effects. Allergic side-effects and liver damage seem to appear with an appreciable lower frequency.
Mechanism of actionChlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Related Articles
AbsorptionIncomplete bioavailability.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationNot Available
Half life8 to 12 hours
ClearanceNot Available
ToxicitySymptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9899
Blood Brain Barrier+0.95
Caco-2 permeable+0.7404
P-glycoprotein substrateSubstrate0.8042
P-glycoprotein inhibitor IInhibitor0.8407
P-glycoprotein inhibitor IIInhibitor0.8884
Renal organic cation transporterInhibitor0.72
CYP450 2C9 substrateNon-substrate0.7199
CYP450 2D6 substrateSubstrate0.6845
CYP450 3A4 substrateSubstrate0.7096
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.768
Ames testNon AMES toxic0.7084
CarcinogenicityNon-carcinogens0.8714
BiodegradationNot ready biodegradable0.9838
Rat acute toxicity3.1665 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8117
hERG inhibition (predictor II)Inhibitor0.7373
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point153-154Sprague, J.M. and Engelhardt, E.L.; US. Patent 2,951,082; August 30, 1960; assigned to Merck & Co., Inc. Schlapfer, R. and Spiegelberg, H.; US. Patent 3,115,502; December 24,1963; assigned to Hoffmann-LaRoche Inc.
water solubility0.295 mg/LNot Available
logP5.18HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.000366 mg/mLALOGPS
logP5.42ALOGPS
logP5.07ChemAxon
logS-5.9ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.66 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.22 KB)
SpectraNot Available
References
Synthesis Reference

Sprague, J.M. and Engelhardt, E.L.; US. Patent 2,951,082; August 30, 1960; assigned to
Merck & Co., Inc.
Schlapfer, R. and Spiegelberg, H.; US. Patent 3,115,502; December 24,1963; assigned to Hoffmann-LaRoche Inc.

US3046283
General ReferencesNot Available
External Links
ATC CodesN05AF03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (63.3 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineChlorprothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineChlorprothixene may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with 7-Nitroindazole.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Chlorprothixene.
AcepromazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Chlorprothixene.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Chlorprothixene.
adipiplonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorprothixene.
AgomelatineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Chlorprothixene.
AlfaxaloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorprothixene.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Chlorprothixene.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorprothixene.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorprothixene.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Chlorprothixene.
AmisulprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorprothixene.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Chlorprothixene.
AmobarbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amperozide.
AmphetamineChlorprothixene may decrease the stimulatory activities of Amphetamine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Chlorprothixene.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorprothixene.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorprothixene.
ArticaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Asenapine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Chlorprothixene.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Chlorprothixene.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Chlorprothixene.
AzaperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Azaperone.
AzelastineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlorprothixene.
BaclofenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chlorprothixene.
BenzphetamineChlorprothixene may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Chlorprothixene.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Chlorprothixene.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorprothixene.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorprothixene.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
BrimonidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorprothixene.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Chlorprothixene.
BrompheniramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorprothixene.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorprothixene.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorprothixene.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorprothixene.
ButacaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorprothixene.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorprothixene.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorprothixene.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Chlorprothixene.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Chlorprothixene.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Chlorprothixene.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Chlorprothixene.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chlorprothixene.
CarbinoxamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Chlorprothixene.
CarisoprodolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carisoprodol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Chlorprothixene.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chlorprothixene.
CetirizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorprothixene.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Chlorprothixene.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorprothixene.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorphenamine.
ChlorphentermineChlorprothixene may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorprothixene.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorzoxazone.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Chlorprothixene.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorprothixene.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Chlorprothixene.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chlorprothixene.
CitalopramThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Chlorprothixene.
ClemastineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Chlorprothixene.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Chlorprothixene.
clomethiazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Chlorprothixene.
ClomipramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Chlorprothixene.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorprothixene.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Chlorprothixene.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorprothixene.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Chlorprothixene.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Chlorprothixene.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Chlorprothixene.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Chlorprothixene.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorprothixene.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chlorprothixene.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorprothixene.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Chlorprothixene.
CyclizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorprothixene.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Chlorprothixene.
CyproheptadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorprothixene.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Chlorprothixene.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Chlorprothixene.
DantroleneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorprothixene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorprothixene.
DapoxetineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dapoxetine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Chlorprothixene.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Chlorprothixene.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Chlorprothixene.
deramciclaneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorprothixene.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Chlorprothixene.
DesloratadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorprothixene.
DetomidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Detomidine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorprothixene.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorprothixene.
DextroamphetamineChlorprothixene may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Chlorprothixene.
DextromoramideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorprothixene.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorprothixene.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Chlorprothixene.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorprothixene.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorprothixene.
DifenoxinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Chlorprothixene.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Chlorprothixene.
DihydrocodeineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorprothixene.
DihydroetorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorprothixene.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Chlorprothixene.
DimenhydrinateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorprothixene.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorprothixene.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Chlorprothixene.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Chlorprothixene.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Chlorprothixene.
DoramectinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Chlorprothixene.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorprothixene.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
DoxylamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlorprothixene.
DrotebanolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorprothixene.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene.
EcgonineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorprothixene.
EfavirenzThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Chlorprothixene.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Chlorprothixene.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chlorprothixene.
EntacaponeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Entacapone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Chlorprothixene.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorprothixene.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorprothixene.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Chlorprothixene.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Chlorprothixene.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Chlorprothixene.
EscitalopramThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorprothixene.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Chlorprothixene.
EstriolThe serum concentration of Estriol can be increased when it is combined with Chlorprothixene.
EstroneThe serum concentration of Estrone can be increased when it is combined with Chlorprothixene.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorprothixene.
EthanolChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Chlorprothixene.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorprothixene.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorprothixene.
EthosuximideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorprothixene.
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Chlorprothixene.
EtorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etorphine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chlorprothixene.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Chlorprothixene.
EzogabineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorprothixene.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Chlorprothixene.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Chlorprothixene.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Chlorprothixene.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Chlorprothixene.
FlibanserinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorprothixene.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorprothixene.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorprothixene.
FluspirileneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorprothixene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Chlorprothixene.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorprothixene.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Chlorprothixene.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Chlorprothixene.
GlutethimideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Glutethimide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Chlorprothixene.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorprothixene.
GuanfacineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Chlorprothixene.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Chlorprothixene.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chlorprothixene.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorprothixene.
HeroinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorprothixene.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorprothixene.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorprothixene.
Hydroxyamphetamine hydrobromideChlorprothixene may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
HydroxyzineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Chlorprothixene.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Chlorprothixene.
IloperidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Chlorprothixene.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Chlorprothixene.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Chlorprothixene.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Chlorprothixene.
IndalpineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Indalpine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Chlorprothixene.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Chlorprothixene.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Chlorprothixene.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorprothixene.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorprothixene.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Chlorprothixene.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorprothixene.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Chlorprothixene.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorprothixene.
KetobemidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Chlorprothixene.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chlorprothixene.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Chlorprothixene.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorprothixene.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Chlorprothixene.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorprothixene.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Chlorprothixene.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Chlorprothixene.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Chlorprothixene.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Chlorprothixene.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chlorprothixene.
LevocabastineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Chlorprothixene.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorprothixene.
LevomilnacipranThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorprothixene.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorprothixene.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Chlorprothixene.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorprothixene.
LisdexamfetamineChlorprothixene may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Chlorprothixene.
LithiumThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Chlorprothixene.
LoratadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorprothixene.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlorprothixene.
LosartanThe serum concentration of Losartan can be increased when it is combined with Chlorprothixene.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorprothixene.
Lu AA21004The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Chlorprothixene.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorprothixene.
MeclizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Chlorprothixene.
MelperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Melperone.
MephentermineChlorprothixene may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorprothixene.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorprothixene.
MequitazineChlorprothixene may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorprothixene.
MetaxaloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methadyl Acetate.
MethamphetamineChlorprothixene may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorprothixene.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Chlorprothixene.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorprothixene.
MethsuximideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorprothixene.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorprothixene.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chlorprothixene.
MetyrosineChlorprothixene may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Chlorprothixene.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Chlorprothixene.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorprothixene.
MilnacipranThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Chlorprothixene.
MirtazapineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlorprothixene.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Chlorprothixene.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorprothixene.
MolindoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Chlorprothixene.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorprothixene.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorprothixene.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.
NabiloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Chlorprothixene.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorprothixene.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorprothixene.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Chlorprothixene.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorprothixene.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorprothixene.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Chlorprothixene.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Chlorprothixene.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Chlorprothixene.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Chlorprothixene.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chlorprothixene.
NitrazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Chlorprothixene.
NormethadoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorprothixene.
OlanzapineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Chlorprothixene.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorprothixene.
OpiumThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Opium.
OrphenadrineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorprothixene.
OsanetantThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Chlorprothixene.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorprothixene.
OxprenololThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorprothixene.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorprothixene.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorprothixene.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Chlorprothixene.
PaliperidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Chlorprothixene.
ParaldehydeChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Chlorprothixene.
ParoxetineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorprothixene.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorprothixene.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorprothixene.
PerampanelThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorprothixene.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorprothixene.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorprothixene.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Chlorprothixene.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlorprothixene.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenoxyethanol.
PhentermineChlorprothixene may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Chlorprothixene.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Chlorprothixene.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorprothixene.
PipamperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chlorprothixene.
PizotifenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Chlorprothixene.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Chlorprothixene.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Chlorprothixene.
PramipexoleChlorprothixene may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chlorprothixene.
PrazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Chlorprothixene.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Chlorprothixene.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Chlorprothixene.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorprothixene.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Chlorprothixene.
PrimidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chlorprothixene.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorprothixene.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorprothixene.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Chlorprothixene.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Chlorprothixene.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Chlorprothixene.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorprothixene.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorprothixene.
PropoxycaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Chlorprothixene.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorprothixene.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorprothixene.
PSD502The risk or severity of adverse effects can be increased when Chlorprothixene is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Chlorprothixene.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorprothixene.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Chlorprothixene.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Chlorprothixene.
QuinineThe serum concentration of Quinine can be increased when it is combined with Chlorprothixene.
RamelteonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Chlorprothixene.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorprothixene.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorprothixene.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorprothixene.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorprothixene.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Chlorprothixene.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorprothixene.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Chlorprothixene.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorprothixene.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Chlorprothixene.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorprothixene.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Chlorprothixene.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorprothixene.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlorprothixene.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Chlorprothixene.
RomifidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Romifidine.
RopiniroleChlorprothixene may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorprothixene.
RotigotineChlorprothixene may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorprothixene.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Chlorprothixene.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Chlorprothixene.
ScopolamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorprothixene.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Chlorprothixene.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Chlorprothixene.
SertindoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorprothixene.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorprothixene.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Chlorprothixene.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Chlorprothixene.
Sodium oxybateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Chlorprothixene.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Chlorprothixene.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorprothixene.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Chlorprothixene.
StiripentolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene.
SulpirideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Chlorprothixene.
SuvorexantThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Chlorprothixene.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Chlorprothixene.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorprothixene.
TasimelteonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorprothixene.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Chlorprothixene.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorprothixene.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Chlorprothixene.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorprothixene.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Chlorprothixene.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorprothixene.
TetracaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetrodotoxin.
ThalidomideChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorprothixene.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorprothixene.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorprothixene.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorprothixene.
ThiothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Chlorprothixene.
TiletamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Chlorprothixene.
TizanidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Chlorprothixene.
TopiramateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorprothixene.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Chlorprothixene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorprothixene.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorprothixene.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Chlorprothixene.
TrazodoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorprothixene.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorprothixene.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorprothixene.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorprothixene.
TriprolidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Chlorprothixene.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Chlorprothixene.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chlorprothixene.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Chlorprothixene.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Chlorprothixene.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Chlorprothixene.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Chlorprothixene.
VigabatrinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Chlorprothixene.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chlorprothixene.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Chlorprothixene.
VortioxetineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorprothixene.
ZiconotideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Chlorprothixene.
ZimelidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlorprothixene.
ZolazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorprothixene.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlorprothixene.
ZonisamideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorprothixene.
ZotepineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Froimowitz M, Cody V: Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists. J Med Chem. 1993 Jul 23;36(15):2219-27. [PubMed:8101879 ]
  2. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565 ]
  3. von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H: Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42. doi: 10.1016/j.bmcl.2008.09.012. Epub 2008 Sep 7. [PubMed:19091563 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Antkiewicz-Michaluk L: The influence of chronic treatment with antidepressant neuroleptics on the central serotonin system. Pol J Pharmacol Pharm. 1986 Jul-Aug;38(4):359-70. [PubMed:3774629 ]
  2. Wander TJ, Nelson A, Okazaki H, Richelson E: Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol. 1987 Nov 10;143(2):279-82. [PubMed:2891550 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23